1. Baker ML, Hutson JM. Serum levels of Müllerian inhibiting substance in boys throughout puberty and in the first two years of life. J Clin Endocrinol Metab. 1993;76(1):245–7.
2. Baker ML, Metcalfe SA, Hutson JM. Serum levels of mullerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab. 1990;70(1):11–5.
3. Behringer RR, Cate RL, Froelick GJ, et al. Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature. 1990;345(6271):167–70.
4. Boehmer AL, Brinkmann AO, Sandkuijl LA, et al. 17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab. 1999;84(12):4713–21.
5. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994;22(15):3181–6.